GABAA receptor subtype selective loreclezole analogues
Disciplines
Chemistry (30%); Medical-Theoretical Sciences, Pharmacy (70%)
Keywords
- Alpha6 Selectivity,
- GABAA receptor,
- Allosteric Modulator,
- Alpha6
GABA-A receptors are channels present in the cell membrane of neurons. Upon binding of the messenger substance GABA they open and allow chloride-ions to flow into the cell. This electrical chloride current is an essential process because it leads to the reduction of excitability of the neuron and thus to a decrease of signalling between neurons. In mammals, GABA-A receptors are formed of five subunits (the most common are alpha, beta and gamma subunits) that can be combined differently. Importantly, GABA is not the only substance that binds to GABA-A receptors, but several clinically used drugs as sleeping aids, antiepileptics, antipanic medications or muscle relaxants do. These drugs bind to several known and unknown binding sites different from the GABA binding site. Recently, putative binding sites for loreclezole, an experimental anticonvulsant, were described to exist in a particular region of the GABA-A receptor. Four loreclezole analogues created by our group showed a clear preference for the subunit alpha6 over alpha1, meaning that these substances bound to the receptor and lead to an increased chloride current only when alpha6 subunits were present. During the past years the alpha6 subunit raised interest thanks to its highly specific expression pattern in the central and peripheral nervous system and its possible involvement in hyper-locomotion, pain perception, inflammation and depression. One of our aims is therefore the generation of alpha6 specific modulatory substances. Our modulators could so be used not only as tool compounds for the detection of alpha6 containing receptors and their distribution in the brain, but on a long term especially as drugs that might be suited to treat some neuropsychiatric conditions. Our second aim is to localize the exact binding site of our substances in the GABA-A receptor. Given that the alpha isoforms differ in only one amino acid of the candidate site, we hypothesize that this amino acid may be responsible for the observed subtype preference. The methods to be used comprise chemical construction of the computationally designed substances, mutations of the one amino acid thought to be responsible for the binding, and an electrophysiological technique to study the chloride currents and their modulation by our substances on the GABA receptors. The binding site with which loreclezole interacts has never been utilized to develop ligands with selectivity for any alpha isoform. Thus, our approach is completely novel and addresses a target of high scientific and medical interest.
The brain must constantly maintain a delicate balance between neuronal excitation and inhibition. A key player in this process is the neurotransmitter GABA (y-aminobutyric acid). GABA acts through GABA-A receptors, which reduce the excitability of neurons. These receptors regulate numerous brain functions and are important targets for drugs used to treat conditions such as anxiety, sleep disorders and epilepsy. Conventional drugs, such as the benzodiazepines, are GABA-A receptor modulators that are highly effective, but limited by severe side effects, including a high risk of dependence and withdrawal symptoms. GABA-A receptors are complex proteins. In mammals, these receptors are formed of five subunits (the most common are alpha, beta and gamma subunits) that can be combined differently, giving rise to numerous receptor subtypes with distinct properties, distributions and functions. This molecular diversity offers an opportunity to develop drugs that act more selectively - provided that individual receptor subtypes can be targeted. For many drugs the binding site within the GABA-A receptor is still unknown. This is where our research has made an important contribution. Our work has advanced our understanding of the structure and pharmacology of GABA-A receptors and their known or presumed binding sites. Particularly intriguing is the 6-subunit. The expression of 6-containing GABA-A receptors is restricted to the cerebellum and trigeminal ganglion. The 6-subunit is thus investigated as a promising target for conditions such as essential tremor, tic-disorders, trigeminal neuropathy, migraine, depression and schizophrenia. Within this project we synthesized 38 new compounds. By means of functional electrophysiological experiments we were able to identify seven compounds that selectively target 6-containing GABA-A receptors while avoiding activity at 1-containing receptors, which may be associated with unwanted adverse effects. This selectivity is particularly noteworthy because the different subunits share considerable structural similarity. To further identify the binding sites of these compounds within the receptor, we combined computational methods and mutational studies. By mutating two 6-specific amino-acids we could show that the selectivity of our compounds is driven primarily by interactions with the well-known etomidate binding site; additional binding sites on the GABA-A receptor partially contribute to the compounds' pharmacological effects. These compounds are now under patent application. The significance of this work extends beyond the discovery of individual compounds. Understanding the etomidate binding site and the discovery of 6-preferring compounds represents an important step towards subunit-selective drug design and the uncoupling of therapeutic efficacy from traditional adverse drug effects.
- Universität Wien - 80%
- Medizinische Universität Wien - 20%
- Margot Ernst, Medizinische Universität Wien , national collaboration partner
- Petra Scholze, Medizinische Universität Wien , associated research partner
- Walter Sandtner, Medizinische Universität Wien , national collaboration partner
- Thomas Seidel, Universität Wien , national collaboration partner
- Vittorio Pace, Universität Wien , national collaboration partner
Research Output
- 3 Citations
- 3 Publications
- 1 Datasets & models
-
2026
Title Nezavist (DCUK-OEt) and aminoquinoline analogues interact with the etomidate site and display a complex mode of modulatory action of the GABAA receptor. DOI 10.1016/j.ejphar.2025.178464 Type Journal Article Author Simeone X Journal European journal of pharmacology Pages 178464 -
2022
Title Apo2ph4 - Automatic Pharmacophore Generation from Apo Protein Structures: Tool Development and Application to the Design and Synthesis of Novel Bio-active Small Molecules Type PhD Thesis Author Jörg Heider -
2022
Title Novel alpha6 preferring GABA-A receptor ligands based on loreclezole DOI 10.1016/j.ejmech.2022.114780 Type Journal Article Author Simeone X Journal European Journal of Medicinal Chemistry Pages 114780
-
2026
Link
Title Novel alpha6 preferring GABA-A receptor ligands based on loreclezole DOI 10.5281/zenodo.22896560 Type Database/Collection of data Public Access Link Link